Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications - Wikidata - awgldk - TriplyDB

Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications

Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications

http://www.wikidata.org/entity/Q28476442

about

Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression Toxicity of amphetamines: an update Impact of methamphetamine on infection and immunity Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes Recent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiology Systems-scale analysis reveals pathways involved in cellular response to methamphetamine Methamphetamine causes acute hyperthermia-dependent liver damage Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.Anti-addiction vaccines.Vaccines against drug abuse.Chronic Methamphetamine Effects on Brain Structure and Function in Rats Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells.Report of methamphetamine use and cardiomyopathy in three patients.A vaccine against methamphetamine attenuates its behavioral effects in mice.Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain.Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension Characterization of the guinea pig animal model and subsequent comparison of the behavioral effects of selective dopaminergic drugs and methamphetamine.Fluoxetine protects against methamphetamine‑induced lung inflammation by suppressing oxidative stress through the SERT/p38 MAPK/Nrf2 pathway in rats.Memory impairment induced by amphetamine derivatives in laboratory animals and in humans: a review.Increased blood 8-hydroxy-2-deoxyguanosine levels in methamphetamine users during early abstinence.Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension.Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models.Oxidative stress status in recently abstinent methamphetamine abusers.Methamphetamine decreases CD4 T cell frequency and alters pro-inflammatory cytokine production in a model of drug abuse.Methamphetamine mediates immune dysregulation in a murine model of chronic viral infection.Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults.Methamphetamine administration modifies leukocyte proliferation and cytokine production in murine tissues Features and Outcomes of Methamphetamine Associated Pulmonary Arterial Hypertension.Is biological aging accelerated in drug addiction?N-acetylcysteine amide protects against methamphetamine-induced tissue damage in CD-1 mice.Distribution measurement of amphetamine-type stimulants in organs using micropulverized extraction and liquid chromatography/tandem mass spectrometry to complement drug distribution using mass spectrometry imaging.Recent Methamphetamine Use is Associated with Increased Rectal Mucosal Inflammatory Cytokines Regardless of HIV-1 Serostatus.DRUG INDUCED PULMONARY ARTERIAL HYPERTENSION: A PRIMER FOR CLINICIANS AND SCIENTISTS.A new approach on methamphetamine-induced hepatotoxicity: involvement of mitochondrial dysfunction.Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.

P2860

Q21089831-02EE1B3A-8C06-42B1-B76B-B3EA64B71E62 Q22252794-F7ED82C6-1805-48C9-8B82-D24B321B407E Q26829217-75185ADC-E602-4D3A-9ED6-E960F04C926E Q28242470-9C555306-4F40-4FF2-8BD5-2B4AA1D4CC04 Q28260273-5827C708-B6FB-4B16-BFC4-6CF09E340017 Q28477826-D60D53F1-1970-4E99-8C89-5B849CC3242E Q34286457-F3915564-728C-4CA1-A30C-5BAF6B952B29 Q35147689-7E466CD8-7F4F-435F-8949-21DF359C49FE Q35263981-771BDA24-1DC3-477E-870D-C03C18653508 Q35938624-467B50BD-D58A-4C1E-9B9C-35D9E3D4880C Q36044768-F86E2B17-5071-411D-81E4-EDB27EA03EFB Q36313032-FBFB535E-A5DF-422B-96B3-C4FB399350AC Q36564458-93DF8790-0A85-41D4-B434-F37A80747415 Q36586100-A11BD292-ABC8-46A4-AC15-725885089468 Q37074706-49487A31-6B2E-4328-9B8A-8F75BF7AEA5C Q37599544-36D3A234-A2F7-42E4-9546-613155AEDDCB Q37693604-12595DB7-38D6-4D4C-BFD9-8C5D40415A84 Q37720119-99E969ED-2FA7-4D37-B08F-1AD1F870BF48 Q38273048-3A0EB169-028F-4149-BCCE-14E7189B5174 Q38654602-8D196533-CA3C-4562-B033-FC5F0264F0B9 Q38803346-FEAAE4C9-73BF-4715-A283-9D8EC3899080 Q38916260-B2DC17F6-CCAC-48D3-A837-A81ACBBE015B Q39462090-B267E645-96FA-4985-8054-64E0A6717F97 Q39624808-DBD4B419-3F07-41B7-8B5A-FBFBA6FE77E5 Q40591612-B8D02AC0-2176-49D3-9B30-6C91C9F244FA Q40705923-6B5D0809-4027-45A3-BD3C-A83A67ADADC5 Q41559203-18C098F5-4217-4D7B-81C3-CF49B49966A5 Q46115864-2B4FBA44-6B2D-4C3C-BEE7-975940FAA3A9 Q48462856-C5DDF7B5-7587-4650-AC27-99221219CF70 Q48649028-5716D4BE-0286-4854-9731-2C48CB2D681F Q48904961-D0C42A48-D1D5-4C4E-8B21-FB9805BCC43E Q50118309-DCB60255-A03F-49EF-AC57-241B417F4FF3 Q50124360-FE9CB02B-D266-49FE-A7CD-0AE5FD0BFEBD Q50232140-EC6D80BE-F61A-49CC-B066-1FFA2DDD0B86 Q52675161-CC67FB1E-8C06-45D4-BD89-9E324568E201

P2860

Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications

http://www.wikidata.org/entity/Q28476442

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Distribution and pharmacokinet ...... an body: clinical implications

@ast

Distribution and pharmacokinet ...... an body: clinical implications

@en

Distribution and pharmacokinet ...... an body: clinical implications

@nl

type

label

Distribution and pharmacokinet ...... an body: clinical implications

@ast

Distribution and pharmacokinet ...... an body: clinical implications

@en

Distribution and pharmacokinet ...... an body: clinical implications

@nl

prefLabel

Distribution and pharmacokinet ...... an body: clinical implications

@ast

Distribution and pharmacokinet ...... an body: clinical implications

@en

Distribution and pharmacokinet ...... an body: clinical implications

@nl

P1433

Q28476442-B8CA2B85-EE85-496F-81FE-8226FBEBDCF3

P1476

Q28476442-14A2F985-CD2E-474B-A6BB-6E4E705DB527

P2093

Q28476442-240F9636-7134-4C8B-A3FF-0034390C68F7

Q28476442-350EF84B-78BB-40DB-8E7E-2A9614AB6258

Q28476442-612BBA6C-C9A2-4D38-9ADB-FBF895896194

Q28476442-CC87F32D-F988-4A54-91AF-2C4A2876C4BE

Q28476442-CFB53CDB-FE83-4FF3-8B91-7AA61283E1C5

Q28476442-DBAE16FA-07F5-42D5-A414-47ECB7BFEC50

Q28476442-FBC72020-E030-4BC3-B9D7-F23BC1A459BD

P2860

Q28476442-081B6B0E-0B37-458D-BCC0-1BAEDECBAAC1

Q28476442-094C9011-0C0F-4EC8-AFEC-EB8D1A9A958C

Q28476442-0FE50EE1-45CF-4083-81EE-BF8CCB4DE0EE

Q28476442-6B263EAA-D9D9-4D7A-83EE-EB4275BAC624

Q28476442-75495ED5-F720-413B-9D46-D7BBAB038CAE

Q28476442-7A4A5ACB-FD78-4860-8184-0F22A53EFB8E

Q28476442-7DF681D2-34E9-4652-9DBB-6865094F34BA

Q28476442-8595DCC4-F7CA-42FA-BE61-4B40E2ECEDD4

Q28476442-860CA5EA-05BB-4C1E-B991-284C27667D9B

Q28476442-898C7FDE-C9C1-4AFE-9D9F-8B9DA61CBF49

P304

Q28476442-12982B7D-5DE9-4E96-A62B-427898B13E8F

P31

Q28476442-7BC3A658-35A8-490A-A90D-DBA5C8F7C43C

P3181

Q28476442-F90B5A08-2C31-4E2B-9430-295AC4F0745B

P356

Q28476442-B9ABF735-486F-47C4-A29A-1B3154865838

P407

Q28476442-81BCA82D-6CCA-4C59-B3B1-3F7B224E1DEB

P433

Q28476442-A8839E56-7EB3-4F39-8270-21D8383B4794

P478

Q28476442-133B584C-9704-4E12-B058-6D80C2D1BEDA

P577

Q28476442-4E3FEDC7-2093-4D64-88D1-3B5E57652519

P5875

Q28476442-06326984-B776-4172-9B32-0804FFE614A4

P698

Q28476442-34AF9411-91A4-4A5A-AA68-61E747A2246D

P921

Q28476442-7E726BB5-EACD-4AED-918A-6F70312DE62F

P932

Q28476442-E12B99D8-EC4A-4B5C-A8FD-B7498DEC063B

P3181

P356

JOURNAL.PONE.0015269

P1433

P1476

Distribution and pharmacokinet ...... an body: clinical implications

@en

P2093

David Alexoff

http://www.w3.org/2001/XMLSchema#string

Elena Shumay

http://www.w3.org/2001/XMLSchema#string

Frank Telang

http://www.w3.org/2001/XMLSchema#string

Gene-Jack Wang

http://www.w3.org/2001/XMLSchema#string

Joanna S Fowler

http://www.w3.org/2001/XMLSchema#string

Nora D Volkow

http://www.w3.org/2001/XMLSchema#string

Peter K Thanos

http://www.w3.org/2001/XMLSchema#string

P2860

Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine

Major physical and psychological harms of methamphetamine use

Genetically correlated effects of selective breeding for high and low methamphetamine consumption.

The rise of methamphetamine in Southeast and East Asia.

Monoaminergic psychomotor stimulants: discriminative stimulus effects and dopamine efflux

The methamphetamine problem in the United States.

The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines.

Effects of smoking on the lung accumulation of [11C]McN5652.

Drug addiction: the neurobiology of behaviour gone awry.

Spontaneous intracerebral hemorrhage related to methamphetamine abuse: autopsy findings and clinical correlation.

P304

e15269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

937909

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0015269

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49677567

http://www.w3.org/2001/XMLSchema#string

P698

21151866

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

2998419

http://www.w3.org/2001/XMLSchema#string